




PROSTATE CANCER RESEARCH AT THE JEFFERSON KIMMEL CANCER CENTER

The **Genitourinary (GU) Cancer Program** is a primary research interest of the Kimmel Cancer Center and a key to the fight against prostate cancer. The goals of the program are to leverage the significant translational and clinical expertise in GU oncology so as to: delineate the mechanisms that underpin GU cancer development and progression, identify novel means to treat advanced disease, and translate these findings into clinical trials that improve disease management. The program focus is on prostate cancer, and includes the following research areas: **1)** disease detection and subtyping, **2)** mechanisms of disease progression, **3)** hormonal regulation and targeting; and **4)** novel targets and therapeutics.

The scientific goals of the program are to:

- 1. Develop new means for detection and subtyping of early stage disease.** In the case of prostate cancer, a major line of investigation is developing early detection mechanisms and ways to discriminate indolent from aggressive local tumors.
- 2. Develop more effective means for treatment of locally advanced disease, and to understand the role of hormone action in this process.** Prostate cancers are influenced by androgen action, and treatment for locally advanced prostate cancer combined hormone therapy with radiation. The program houses significant expertise in the areas of androgen signaling and radiotherapy.
- 3. Determine the mechanisms by which tumors escape hormone therapy, and to develop strategies for treating the advanced stages of the disease.** New therapeutic strategies are urgently needed to treat the later stages of the disease, and our program members are leading experts in this area.
- 4. Develop means to stratify patients so as to improve therapeutic outcomes.** Personalized medicine is a major theme of the program, and clinical trials are currently being designed based on basic science and pre-clinical studies of program investigators.



Karen Knudsen PhD, Program Leader, is Professor of Cancer Biology Urology, and Radiation Oncology and is an internationally recognized researcher in hormonal action and androgen receptor signaling in prostate cancer. Dr. Knudsen has received numerous awards for her scientific achievements in the study of androgen action in the pathogenesis of prostate cancer, mentoring of students and fellows, and for her service to the global scientific community. She is frequently called upon to lecture worldwide in the area of translational research in prostate cancer.



Leonard G. Gomella, MD, Program Clinical Leader is the Bernard Godwin Professor of Prostate Cancer Professor and Chair of The Department of Urology, Thomas Jefferson University, and Associate Director of Clinical Affairs for the Kimmel Cancer Center. He is internationally recognized for his work in clinical management and research on prostate cancer and other urological malignancies. Dr. Gomella has given almost 500 presentations at local, national and international meetings and written over 300 papers, chapters and monographs in the field most notably on research and treatment of prostate cancer.



PROSTATE CANCER CARE AT THE JEFFERSON KIMMEL CANCER CENTER

The Challenge

Each year, more than 240,000 American men learn they have prostate cancer. Prostate cancer is the most commonly diagnosed solid tumor in men in the United States accounting for an estimated 28% of all new cancers diagnosed. It is the second most common type of cancer among men in this country. Major risk factors include: age over 65 years (the chance of getting prostate cancer increases as you get older), family history of the disease, and race (African Americans have an increased risk of the disease).

Treatment at Jefferson's Kimmel Cancer Center

At Jefferson's Kimmel Cancer Center, our physicians and researchers are dedicated to providing the best clinical care for men with prostate cancer, to bringing the latest research developments from the laboratory to patients who need them, and to the development of innovative new diagnostic and treatment options to help in the fight against this disease. Research in the war against prostate cancer is a primary focus of the **Genitourinary (GU) Cancer Program** is at the Kimmel Cancer Center.

Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The best option depends on several factors including the patient's age and overall health, the aggressiveness of the cancer (grade of the tumor and the number of biopsy tissue samples that contain cancer cells), the stage of the cancer, current symptoms, and informed discussions between the patient and the physicians. Treatment options for early stage cancers can vary from active surveillance, surgical removal of the prostate, including robotic prostatectomy, and various types of radiation therapy including radioactive seeds. For more advanced prostate cancer hormone therapy, immunotherapy and chemotherapy are common options. Cutting edge experimental protocols are also available at our NCI designated Cancer Center.

The Prostate Cancer Team at the Kimmel Cancer Center

A dedicated team of Kimmel Cancer Center physicians at the Jefferson Kimmel Cancer Center assesses the needs of each new patient and develops a personalized treatment plan that gives each patient the best opportunity to beat this disease and lead a normal healthy life. Our **Genitourinary (GU) Multidisciplinary Clinic**, co-founded by Dr. Leonard Gomella, has been in operation since 1996 and has been internationally recognized for improving the survival of men with more aggressive forms of prostate cancer. Patients are seen by multiple specialists during one comprehensive visit to the KCC, a true multidisciplinary approach to prostate cancer. Our multidisciplinary clinical team includes the following physicians:

Department of Urology: Leonard G. Gomella, MD, Edouard J. Trabulsi, MD & Costas D. Lallas, MD.

Department of Radiation Oncology: Adam Dicker, MD, PhD, Timothy Showalter, MD & Bobby Den, MD

Department of Medical Oncology: William Kevin Kelly, DO, Jianqing Lin, MD & Jean Hoffman-Censits, MD

These clinicians are supported by a full complement of other specialist physicians, nurses, social workers, support groups, a "Buddy" Program, the Brind Center for Integrative and Complementary Medicine, clinical trials coordinators and a dedicated prostate Cancer Coordinator. This range of resources can be found at our academic medical center located at Thomas Jefferson University Hospital, rated as one of the best for Cancer Care by U.S. *News and World Report*.

Patients can call **1-800-JEFF-NOW** for an appointment at our multidisciplinary center.